Loading ...
Sorry, an error occurred while loading the content.

NEWS: FDA experts spurn Abbott drug

Expand Messages
  • Vincent
    Advisory panel recommends full agency not approve atrasentan, a treatment for prostate cancer. September 13, 2005: 2:46 PM EDT By Aaron Smith, CNN/Money staff
    Message 1 of 1 , Sep 16, 2005
    View Source
    • 0 Attachment
      Advisory panel recommends full agency not approve atrasentan, a
      treatment for prostate cancer.
      September 13, 2005: 2:46 PM EDT
      By Aaron Smith, CNN/Money staff writer

      NEW YORK (CNN/Money) - An FDA expert panel voted unanimously Tuesday
      not to recommend atrasentan, an Abbott Laboratories drug candidate that
      the company says would stop the spread of prostate cancer and fight
      bone pain.


      http://money.cnn.com/2005/09/13/news/fortune500/abbott/index.htm
    Your message has been successfully submitted and would be delivered to recipients shortly.